 |
|
|
|
 |
|
|
 Contact |  Print version |  PDF version |  Recommend company
|
Gustav Wieds Vej 10
8000 Aarhus C
Denmark
|
|
Portrait
Borean Pharma was established with the objective to develop a new generation of pharmaceutical protein products. The company's competitive advantage lies in its proprietary technology, enabling it to develop a new generation of highly efficacious compounds and antibody analogues that can be produced in E. coli. The ease of production addresses a major shortcoming of monoclonal antibodies. Borean Pharma believes that it can unleash the true potential of biopharmaceuticals by providing efficacious and costeffective protein-based antibody analogues. The Company recently licensed its lead for atherosclerosis, Apo-AI, to Roche and, among other programmes, is also developing a TNF antagonist for Rheumatoid Arthritis. Borean was founded in 2001 as a spin-off from Aarhus University The firm has been backed by an investment syndicate consisting of Forbion Capital Partners, Aravis Venture, BankInvest Biomedical Venture, INCUBA Venture and NOVI.
Industrial Sectors
Additional information
Borean Pharma A/S
Aarhus C, Denmark
News
|
|
|
|
|
|
Top
